What is the main purpose of this 8-K filing?

This 8-K filing serves to report Amgen's unaudited financial results for the first quarter ended March 31, 2008, and to provide additional context on how the company views its ongoing operational performance through the use of non-GAAP financial measures.

What types of expenses does Amgen exclude in its non-GAAP reporting for Q1 2008?

Amgen excludes expenses related to the expensing of stock options (SFAS No. 123R), costs associated with its 2007 restructuring plan (severance, asset impairments), and acquisition-related costs (including amortization of acquired intangibles and merger expenses) from its non-GAAP financial measures.

Why does Amgen present non-GAAP financial measures?

Amgen believes that presenting non-GAAP financial measures provides useful supplementary information to investors. These measures help to facilitate additional analysis by removing the impact of certain expenses and charges that may be non-recurring or non-cash, allowing for a clearer comparison of the company's underlying operational performance across different periods.

What specific acquisitions are mentioned as impacting the financial reporting adjustments?

The acquisitions mentioned that lead to adjustments in the financial reporting include Alantos Pharmaceutical Holding, Inc. (Alantos), Avidia, Inc. (Avidia), Abgenix, Inc. (Abgenix), and Immunex Corporation (Immunex).

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on April 24, 2008, reporting its unaudited financial results for the first quarter ended March 31, 2008. The report primarily details the company's non-GAAP financial measures, which exclude certain one-time or non-cash items to provide a clearer view of ongoing operational performance. Key adjustments made for the first quarter of 2008 include the impact of expensing stock options (SFAS No. 123R), costs associated with a 2007 restructuring plan, and expenses related to acquisitions, such as Alantos, Avidia, Abgenix, and Immunex. The company believes these non-GAAP measures offer valuable supplementary information for investors to analyze performance trends and make comparisons across periods, especially concerning the integration of acquired assets and restructuring efforts.

Key Highlights

1Amgen released its Q1 2008 financial results via an 8-K filing on April 24, 2008.
2The report emphasizes the use of non-GAAP financial measures to present operational performance.
3Key exclusions in non-GAAP reporting for Q1 2008 include stock option expensing (SFAS No. 123R), restructuring charges, and acquisition-related costs.
4Acquisitions mentioned as contributing to adjusted figures include Alantos, Avidia, Abgenix, and Immunex.
5Amgen believes these non-GAAP measures facilitate better period-to-period comparisons by removing unusual or non-recurring items.
6The company also provided non-GAAP adjusted earnings per share including stock option expensing as a convenience for investors.

AMGEN INC 8-K Report, Financial Results (Apr 24, 2008)

Summary

Key Highlights

Frequently Asked Questions